Quarterly ResultMay 15, 2026, 07:57 AM
Immuneering Q1 Net Loss $(13.46)M; Cash & Equiv. $47.32M
AI Summary
Immuneering Corp. reported a net loss of $13.46 million for the first quarter of 2026, an improvement from the $15.05 million net loss in the same period last year. The net loss per share also improved to $(0.21) from $(0.42). The company ended the quarter with $47.32 million in cash and cash equivalents and $109.37 million in current marketable securities. Research and development expenses decreased, while general and administrative expenses rose. Immuneering estimates its current cash and marketable securities will fund operations for at least 12 months.
Key Highlights
- Net loss for Q1 2026 was $13.46 million, an improvement from $15.05 million in Q1 2025.
- Net loss per share was $(0.21) for Q1 2026, compared to $(0.42) for Q1 2025.
- Cash and cash equivalents totaled $47.32 million as of March 31, 2026.
- Current marketable securities increased to $109.37 million as of March 31, 2026.
- Research and development expenses decreased to $10.65 million from $11.47 million year-over-year.
- General and administrative expenses increased to $4.68 million from $4.01 million year-over-year.
- Accumulated deficit reached $293.8 million as of March 31, 2026.
- Company estimates cash, cash equivalents, and marketable securities will fund operations for at least 12 months.
Price Impact
More from IMRX